MX2015001318A - Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona. - Google Patents
Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona.Info
- Publication number
- MX2015001318A MX2015001318A MX2015001318A MX2015001318A MX2015001318A MX 2015001318 A MX2015001318 A MX 2015001318A MX 2015001318 A MX2015001318 A MX 2015001318A MX 2015001318 A MX2015001318 A MX 2015001318A MX 2015001318 A MX2015001318 A MX 2015001318A
- Authority
- MX
- Mexico
- Prior art keywords
- lower alkyl
- halogen
- substituted
- disease
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
La presente invención se refiere a compuestos de la fórmula general I: (ver Fórmula) en donde: R1 es hidrógeno, halógeno, alquilo inferior, alcoxi inferior, alcoxi inferior sustituido por halógeno o ciano; R2 es hidrógeno, alquilo inferior o alquilo inferior sustituido por halógeno; R3 es fenilo, benzo[1,3]dioxolilo, 2,3-dihidro-benzofuran-5-ilo o un heteroarilo de 5 ó 6 miembros, tales grupos fenilo y heteroarilo de 5 ó 6 miembros pueden estar sustituidos por uno o más sustituyentes elegidos entre ciano, nitro, amino y di(alquilo inferior)-amino, (alquilo inferior) -sulfonilo, alcoxi inferior, alcoxi inferior sustituido por halógeno, halógeno, alquilo inferior, alquilo inferior sustituido por halógeno o alquilo inferior sustituido por hidroxilo; X es -CH(alquilo inferior)-, -CH2-, -CH2CH2- o - CH(alquilo inferior)CH2-; R es hidrógeno o alquilo inferior; n s el número 1 ó 2; o una sal de adición de ácido farmacéuticamente aceptable, una mezcla racémica o su enantiómero correspondiente y/o sus isómeros ópticos. Los compuestos pueden utilizarse para el tratamiento de la esquizofrenia, los trastornos de personalidad obsesivo-compulsivos, la depresión mayor, los trastornos bipolares, los trastornos de ansiedad, el envejecimiento normal, la epilepsia, la degeneración de la retina, la lesión cerebral traumática, la lesión de la espina dorsal, el trastorno de estrés post-traumático, el trastorno de pánico, la enfermedad de Parkinson, la demencia, la enfermedad de Alzheimer, el desequilibrio cognitivo leve, la disfunción cognitiva inducida por la quimioterapia, el síndrome de Down, los trastornos del espectro autista, la pérdida auditiva, el tintineo, la ataxia espinocerebelar, la esclerosis lateral amiotrófica, la esclerosis múltiple, la enfermedad de Huntington, la apoplejía, la terapia radiactiva, el estrés crónico, el abuso de drogas neuroactivas, por ejemplo el alcohol, los opiáceos, la metanfetamina, fenciclidina y cocaína.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12179381 | 2012-08-06 | ||
| PCT/EP2013/066344 WO2014023674A1 (en) | 2012-08-06 | 2013-08-05 | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015001318A true MX2015001318A (es) | 2015-04-17 |
| MX362184B MX362184B (es) | 2019-01-08 |
Family
ID=48918402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015001318A MX362184B (es) | 2012-08-06 | 2013-08-05 | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9284321B2 (es) |
| EP (1) | EP2880036B1 (es) |
| JP (1) | JP5974177B2 (es) |
| KR (1) | KR101716062B1 (es) |
| CN (1) | CN104540829B (es) |
| AR (1) | AR092041A1 (es) |
| AU (1) | AU2013301577B2 (es) |
| BR (1) | BR112015000313A2 (es) |
| CA (1) | CA2880682A1 (es) |
| CL (1) | CL2015000143A1 (es) |
| CO (1) | CO7141435A2 (es) |
| CR (1) | CR20140545A (es) |
| EA (1) | EA025884B1 (es) |
| HK (1) | HK1206355A1 (es) |
| IL (1) | IL236808B (es) |
| MA (1) | MA37791B1 (es) |
| MX (1) | MX362184B (es) |
| MY (1) | MY185216A (es) |
| NZ (1) | NZ703192A (es) |
| PE (1) | PE20150341A1 (es) |
| PH (1) | PH12015500059A1 (es) |
| SG (1) | SG11201408529VA (es) |
| TW (1) | TWI506027B (es) |
| UA (1) | UA113013C2 (es) |
| WO (1) | WO2014023674A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4089397A1 (en) * | 2013-02-18 | 2022-11-16 | Labrador Diagnostics LLC | System for optically analyzing a sample |
| EP2981538B1 (en) * | 2013-04-02 | 2017-08-02 | F. Hoffmann-La Roche AG | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one |
| WO2015036412A1 (en) * | 2013-09-12 | 2015-03-19 | F. Hoffmann-La Roche Ag | Indol-carboxamide derivatives |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1965981C3 (de) * | 1968-02-13 | 1978-08-31 | Sumitomo Chemical Co., Ltd., Osaka (Japan) | 9-Phenyl-lO-oxopiperazino [l,2-a]-indole und Verfahren zu ihrer Herstellung |
| GB0106177D0 (en) * | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| GB0202015D0 (en) * | 2002-01-29 | 2002-03-13 | Hoffmann La Roche | Piperazine Derivatives |
| WO2007065820A1 (en) * | 2005-12-09 | 2007-06-14 | F. Hoffmann-La Roche Ag | Tricyclic amide derivatives useful for treating obesity |
| WO2008046072A2 (en) | 2006-10-13 | 2008-04-17 | The Board Of Regents Of The University Of Texas System | Chemical inducers of neurogenesis |
| JP2010509259A (ja) * | 2006-11-09 | 2010-03-25 | エフ．ホフマン−ラ ロシュ アーゲー | インドール及びベンゾフラン２−カルボキサミド誘導体 |
| WO2012006419A2 (en) | 2010-07-07 | 2012-01-12 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| EP2981538B1 (en) * | 2013-04-02 | 2017-08-02 | F. Hoffmann-La Roche AG | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one |
-
2013
- 2013-08-05 PE PE2015000024A patent/PE20150341A1/es active IP Right Grant
- 2013-08-05 KR KR1020157003112A patent/KR101716062B1/ko active IP Right Grant
- 2013-08-05 CN CN201380041546.5A patent/CN104540829B/zh active Active
- 2013-08-05 CA CA2880682A patent/CA2880682A1/en not_active Abandoned
- 2013-08-05 EA EA201590125A patent/EA025884B1/ru not_active IP Right Cessation
- 2013-08-05 SG SG11201408529VA patent/SG11201408529VA/en unknown
- 2013-08-05 AU AU2013301577A patent/AU2013301577B2/en not_active Ceased
- 2013-08-05 MY MYPI2014003519A patent/MY185216A/en unknown
- 2013-08-05 EP EP13745648.9A patent/EP2880036B1/en active Active
- 2013-08-05 AR ARP130102771A patent/AR092041A1/es unknown
- 2013-08-05 UA UAA201501071A patent/UA113013C2/uk unknown
- 2013-08-05 JP JP2015525846A patent/JP5974177B2/ja active Active
- 2013-08-05 MX MX2015001318A patent/MX362184B/es active IP Right Grant
- 2013-08-05 TW TW102128001A patent/TWI506027B/zh not_active IP Right Cessation
- 2013-08-05 WO PCT/EP2013/066344 patent/WO2014023674A1/en active Application Filing
- 2013-08-05 NZ NZ703192A patent/NZ703192A/en not_active IP Right Cessation
- 2013-08-05 BR BR112015000313A patent/BR112015000313A2/pt not_active Application Discontinuation
-
2014
- 2014-11-27 CR CR20140545A patent/CR20140545A/es unknown
- 2014-11-28 CO CO14262433A patent/CO7141435A2/es unknown
-
2015
- 2015-01-09 PH PH12015500059A patent/PH12015500059A1/en unknown
- 2015-01-19 IL IL236808A patent/IL236808B/en not_active IP Right Cessation
- 2015-01-20 MA MA37791A patent/MA37791B1/fr unknown
- 2015-01-21 CL CL2015000143A patent/CL2015000143A1/es unknown
- 2015-02-04 US US14/614,232 patent/US9284321B2/en active Active
- 2015-07-24 HK HK15107077.4A patent/HK1206355A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016008842A (es) | Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos. | |
| MX362532B (es) | Derivados de 1,7-naftiridina. | |
| MX2015015052A (es) | Derivados de isoquinolina que estimulan la neurogenesis. | |
| MX2015006364A (es) | 1,6-naftiridinas sustituidas. | |
| AR093576A1 (es) | Derivados heterociclicos sustituidos | |
| MX2016008983A (es) | Peliculas termocontraibles de barrera de multicapa pvdc. | |
| PH12016502231A1 (en) | Indolin-2-one or pyrrolo-pyridin-2-one derivatives | |
| MX2015017343A (es) | Derivados de pirrolopiridina o pirazolopiridina. | |
| RU2015112914A (ru) | Бензимидазолы в качестве активных агентов для центральной нервной системы | |
| MX2016008536A (es) | Derivados de fluoro-naftilo. | |
| PH12015500059B1 (en) | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one | |
| PH12016500605A1 (en) | Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders | |
| BR112015008200A2 (pt) | derivados de imidazopiridina | |
| MX2015013915A (es) | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona. | |
| MX363461B (es) | Derivados de benzisoxazol como moduladores de la neurogénesis y el uso de los mismos en el tratamiento de enfermedades neurológicas y trastornos neuropsiquiátricos. | |
| MX2016001528A (es) | Derivados de indol-carboxamida. | |
| TH165816A (th) | ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท | |
| TH165816B (th) | ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท | |
| TH167754A (th) | ไพเพอราซิโน[1,2-a]อินดอล-1-โอนและ[1,4]ไดอะซีพิโน[1,2-a]อินดอล-1-โอน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |